Compare $VRDN vs $ZBIO | Chartloom

Compare

$VRDN vs $ZBIO

Viridian Therapeutics Inc · Zenas Biopharma Inc

VRDN

Viridian Therapeutics Inc

ZBIO

Zenas Biopharma Inc

Compare $VRDN vs $ZBIO

Comparing Viridian Therapeutics Inc and Zenas Biopharma Inc

VRDNViridian Therapeutics Inc

ZBIOZenas Biopharma Inc

VRDNViridian Therapeutics Inc

Market cap

$2.06B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

14.59x

Rev growth (TTM)

23220.3%

YTD performance

-39.2%

52W performance

-12.6%

FCF yield

-16.3%

ZBIOZenas Biopharma Inc

Market cap

$1.72B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-93.3%

YTD performance

-21.0%

52W performance

5.3%

FCF yield

-16.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

VRDN

ZBIO

Detailed metrics comparison

VRDN

Viridian Therapeutics Inc

ZBIO

Zenas Biopharma Inc

Market Cap

VRDN$2.06B

ZBIO$1.72B

Enterprise Value

VRDN$2.25B

ZBIO$1.91B

Price

VRDN$18.66

ZBIO$27.26

P/E Ratio

VRDNN/A

ZBION/A

P/S Ratio

VRDN28.97x

ZBIO1,720.92x

EV/Sales

VRDN31.65x

ZBIO1,913.10x

EV/EBITDA

VRDN0.00x

ZBIO0.00x

P/B Ratio

VRDN3.58x

ZBIO7.47x

P/FCF Ratio

VRDNN/A

ZBION/A

EV/FCF

VRDN-6.72x

ZBIO-6.57x

PEG Ratio

VRDNN/A

ZBION/A

Forward P/E (NTM)

VRDNN/A

ZBION/A

Forward P/S (NTM)

VRDN14.59x

ZBION/A

Revenue (TTM)

VRDN$71M

ZBIO$1M

Revenue Growth (YoY)

VRDN23220.3%

ZBIO-93.3%

Forward Rev Growth

VRDN729.0%

ZBIO5296.9%

Gross Margin (TTM)

VRDN2.4%

ZBIO0.0%

Operating Margin (TTM)

VRDN0.0%

ZBIO0.0%

EBITDA Margin (TTM)

VRDN-569.0%

ZBIO-27387.0%

Net Margin (TTM)

VRDN-544.1%

ZBIO-48438.4%

FCF Margin (TTM)

VRDN-471.0%

ZBIO-29097.4%

Net Income (TTM)

VRDN$-387M

ZBIO$-484M

FCF (TTM)

VRDN$-335M

ZBIO$-291M

EPS (TTM)

VRDN-$3.59

ZBIO-$7.67

ROE (TTM)

VRDN-6135.0%

ZBIO-18968.0%

ROA (TTM)

VRDN-4603.0%

ZBIO-8991.0%

ROIC (TTM)

VRDN-5041.0%

ZBIO-10131.0%

Cash

VRDN$165M

ZBIO$197M

Debt

VRDN$356M

ZBIO$389M

Net Cash/Debt

VRDN$-191M

ZBIO$-192M

Current Ratio (TTM)

VRDN16.95x

ZBIO9.93x

Quick Ratio (TTM)

VRDN16.56x

ZBIO9.77x

Debt/Equity (TTM)

VRDN0.54x

ZBIO1.57x

Debt/Assets (TTM)

VRDN0.0%

ZBIO0.0%

Interest Coverage (TTM)

VRDNN/A

ZBION/A

Net Debt/EBITDA (TTM)

VRDN0.00x

ZBIO0.00x

Beta

VRDN1.11

ZBIO0.70

52W Performance

VRDN-12.6%

ZBIO5.3%

YTD Performance

VRDN-39.2%

ZBIO-21.0%

% from 52W High

VRDN-45.6%

ZBIO-38.9%

% from 52W Low

VRDN41.6%

ZBIO101.9%

Asset Turnover (TTM)

VRDN0.08x

ZBIO0.00x

FCF Yield (TTM)

VRDN-16.3%

ZBIO-16.9%

Earnings Yield (TTM)

VRDN-18.8%

ZBIO-28.1%

Dividend Yield (TTM)

VRDNN/A

ZBION/A

Rule of 40

VRDN22,749.3

ZBIO-29,190.7

EV/GP/RG

VRDN8.67

ZBION/A

Ticker research

View VRDN research View ZBIO research

Metric	VRDN Viridian Therapeutics Inc	ZBIO Zenas Biopharma Inc
Market & Valuation
Market Cap	$2.06B	$1.72B
Enterprise Value	$2.25B	$1.91B
Price	$18.66	$27.26
P/E Ratio	N/A	N/A
P/S Ratio	28.97x	1,720.92x
EV/Sales	31.65x	1,913.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.58x	7.47x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.72x	-6.57x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	14.59x	N/A
Revenue & Growth
Revenue (TTM)	$71M	$1M
Revenue Growth (YoY)	23220.3%	-93.3%
Forward Rev Growth	729.0%	5296.9%
Profitability
Gross Margin (TTM)	2.4%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-569.0%	-27387.0%
Net Margin (TTM)	-544.1%	-48438.4%
FCF Margin (TTM)	-471.0%	-29097.4%
Net Income (TTM)	$-387M	$-484M
FCF (TTM)	$-335M	$-291M
EPS (TTM)	-$3.59	-$7.67
ROE (TTM)	-6135.0%	-18968.0%
ROA (TTM)	-4603.0%	-8991.0%
ROIC (TTM)	-5041.0%	-10131.0%
Financial Health
Cash	$165M	$197M
Debt	$356M	$389M
Net Cash/Debt	$-191M	$-192M
Current Ratio (TTM)	16.95x	9.93x
Quick Ratio (TTM)	16.56x	9.77x
Debt/Equity (TTM)	0.54x	1.57x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.11	0.70
52W Performance	-12.6%	5.3%
YTD Performance	-39.2%	-21.0%
% from 52W High	-45.6%	-38.9%
% from 52W Low	41.6%	101.9%
Efficiency & Yields
Asset Turnover (TTM)	0.08x	0.00x
FCF Yield (TTM)	-16.3%	-16.9%
Earnings Yield (TTM)	-18.8%	-28.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	22,749.3	-29,190.7
EV/GP/RG	8.67	N/A
Ticker research	View VRDN research	View ZBIO research

Valuation

P/S Ratio

VRDN

28.97x

ZBIO

1,720.92x

EV/FCF

VRDN

-6.72x

ZBIO

-6.57x

Growth & revenue

Revenue Growth TTM

VRDN

23220.3%

ZBIO

-93.3%

Forward Revenue Growth

ZBIO

5296.9%

VRDN

729.0%

Profitability & performance

Gross Margin

VRDN

2.4%

ZBIO

0.0%

ROE

VRDN

-6135.0%

ZBIO

-18968.0%

FCF Yield %

VRDN

-16.3%

ZBIO

-16.9%

52-Week Performance

ZBIO

5.3%

VRDN

-12.6%

Detailed metrics comparison

VRDN

Viridian Therapeutics Inc

ZBIO

Zenas Biopharma Inc

Market Cap

VRDN$2.06B

ZBIO$1.72B

Enterprise Value

VRDN$2.25B

ZBIO$1.91B

Price

VRDN$18.66

ZBIO$27.26

P/E Ratio

VRDNN/A

ZBION/A

P/S Ratio

VRDN28.97x

ZBIO1,720.92x

EV/Sales

VRDN31.65x

ZBIO1,913.10x

EV/EBITDA

VRDN0.00x

ZBIO0.00x

P/B Ratio

VRDN3.58x

ZBIO7.47x

P/FCF Ratio

VRDNN/A

ZBION/A

EV/FCF

VRDN-6.72x

ZBIO-6.57x

PEG Ratio

VRDNN/A

ZBION/A

Forward P/E (NTM)

VRDNN/A

ZBION/A

Forward P/S (NTM)

VRDN14.59x

ZBION/A

Revenue (TTM)

VRDN$71M

ZBIO$1M

Revenue Growth (YoY)

VRDN23220.3%

ZBIO-93.3%

Forward Rev Growth

VRDN729.0%

ZBIO5296.9%

Gross Margin (TTM)

VRDN2.4%

ZBIO0.0%

Operating Margin (TTM)

VRDN0.0%

ZBIO0.0%

EBITDA Margin (TTM)

VRDN-569.0%

ZBIO-27387.0%

Net Margin (TTM)

VRDN-544.1%

ZBIO-48438.4%

FCF Margin (TTM)

VRDN-471.0%

ZBIO-29097.4%

Net Income (TTM)

VRDN$-387M

ZBIO$-484M

FCF (TTM)

VRDN$-335M

ZBIO$-291M

EPS (TTM)

VRDN-$3.59

ZBIO-$7.67

ROE (TTM)

VRDN-6135.0%

ZBIO-18968.0%

ROA (TTM)

VRDN-4603.0%

ZBIO-8991.0%

ROIC (TTM)

VRDN-5041.0%

ZBIO-10131.0%

Cash

VRDN$165M

ZBIO$197M

Debt

VRDN$356M

ZBIO$389M

Net Cash/Debt

VRDN$-191M

ZBIO$-192M

Current Ratio (TTM)

VRDN16.95x

ZBIO9.93x

Quick Ratio (TTM)

VRDN16.56x

ZBIO9.77x

Debt/Equity (TTM)

VRDN0.54x

ZBIO1.57x

Debt/Assets (TTM)

VRDN0.0%

ZBIO0.0%

Interest Coverage (TTM)

VRDNN/A

ZBION/A

Net Debt/EBITDA (TTM)

VRDN0.00x

ZBIO0.00x

Beta

VRDN1.11

ZBIO0.70

52W Performance

VRDN-12.6%

ZBIO5.3%

YTD Performance

VRDN-39.2%

ZBIO-21.0%

% from 52W High

VRDN-45.6%

ZBIO-38.9%

% from 52W Low

VRDN41.6%

ZBIO101.9%

Asset Turnover (TTM)

VRDN0.08x

ZBIO0.00x

FCF Yield (TTM)

VRDN-16.3%

ZBIO-16.9%

Earnings Yield (TTM)

VRDN-18.8%

ZBIO-28.1%

Dividend Yield (TTM)

VRDNN/A

ZBION/A

Rule of 40

VRDN22,749.3

ZBIO-29,190.7

EV/GP/RG

VRDN8.67

ZBION/A

Ticker research

View VRDN research View ZBIO research

Metric	VRDN Viridian Therapeutics Inc	ZBIO Zenas Biopharma Inc
Market & Valuation
Market Cap	$2.06B	$1.72B
Enterprise Value	$2.25B	$1.91B
Price	$18.66	$27.26
P/E Ratio	N/A	N/A
P/S Ratio	28.97x	1,720.92x
EV/Sales	31.65x	1,913.10x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.58x	7.47x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.72x	-6.57x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	14.59x	N/A
Revenue & Growth
Revenue (TTM)	$71M	$1M
Revenue Growth (YoY)	23220.3%	-93.3%
Forward Rev Growth	729.0%	5296.9%
Profitability
Gross Margin (TTM)	2.4%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-569.0%	-27387.0%
Net Margin (TTM)	-544.1%	-48438.4%
FCF Margin (TTM)	-471.0%	-29097.4%
Net Income (TTM)	$-387M	$-484M
FCF (TTM)	$-335M	$-291M
EPS (TTM)	-$3.59	-$7.67
ROE (TTM)	-6135.0%	-18968.0%
ROA (TTM)	-4603.0%	-8991.0%
ROIC (TTM)	-5041.0%	-10131.0%
Financial Health
Cash	$165M	$197M
Debt	$356M	$389M
Net Cash/Debt	$-191M	$-192M
Current Ratio (TTM)	16.95x	9.93x
Quick Ratio (TTM)	16.56x	9.77x
Debt/Equity (TTM)	0.54x	1.57x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.11	0.70
52W Performance	-12.6%	5.3%
YTD Performance	-39.2%	-21.0%
% from 52W High	-45.6%	-38.9%
% from 52W Low	41.6%	101.9%
Efficiency & Yields
Asset Turnover (TTM)	0.08x	0.00x
FCF Yield (TTM)	-16.3%	-16.9%
Earnings Yield (TTM)	-18.8%	-28.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	22,749.3	-29,190.7
EV/GP/RG	8.67	N/A
Ticker research	View VRDN research	View ZBIO research